Heyman Richard A.'s most recent trade in ORIC Pharmaceuticals Inc was a trade of 3,500 Common Stock done at an average price of $12.0 . Disclosure was reported to the exchange on Jan. 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ORIC Pharma Inc | Richard A. Heyman | Director | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 16 Jan 2026 | 3,500 | 41,800 | - | 12.0 | 42,016 | Common Stock |
| ORIC Pharma Inc | Richard A. Heyman | Director | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 16 Jan 2026 | 3,200 | 213,072 | - | 12.0 | 38,415 | Common Stock |
| ORIC Pharma Inc | Richard A. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Richard A. Heyman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 03 Oct 2025 | 31,353 | 43,853 | - | 1.6 | 50,165 | Common Stock |
| ORIC Pharma Inc | Richard A. Heyman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 18,125 | 0 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Richard A. Heyman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 13,228 | 33,700 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Richard A. Heyman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 1,447 | 52,253 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Richard A. Heyman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.75 per share. | 03 Oct 2025 | 1,447 | 45,300 | - | 3.7 | 5,426 | Common Stock |
| ORIC Pharma Inc | Richard A. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Richard A. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 25,600 | 25,600 | - | - | Stock Option (right to buy) | |
| RayzeBio Inc | Heyman Richard A. | Director | Sale or transfer of securities back to the company at price $ 62.50 per share. | 26 Feb 2024 | 367,446 | 0 | - | 62.5 | 22,965,375 | Common Stock |
| ORIC Pharma Inc | Heyman A. Richard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Gritstone Bio Inc | Richard A. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | Richard A. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) |